PL

Non-commercial clinical research conducted at the MUG

StartNon-commercial clinical res...
Department of Non-Commercial Clinical ResearchDepartment of Academic CROSupporting structures: Early Phase Clinical Research Center
Our teamContact
Project MCWBKNon-commercial clinical research conducted at the MUG
Current contestsMedical Research Agency

The Medical University of Gdańsk is one of the applicants with the largest number of projects that have received funding from the Medical Research Agency (MRA) to support non-commercial clinical research. Currently, the MUG is a leader of 15 research and scientific projects. The total value of funding received from MRA is over 191 million PLN.


Clinical trial projects funded by MRA:

• ADONIS-PCI Dual antithrombotic therapy with Dabigatran and Ticagrelor in patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation undergoing percutaneous coronary intervention [2019/ABM/01/00027]. Leader: Prof. Miłosz Jaguszewski from 1st Department of Cardiology of the MUG, funding in the amount of 13,180 mln PLN.

• ERICONS Early treatment with rituximab children with idiopathic nephrotic syndrome [2019/ABM/01/00024]. Leader: Prof. Aleksandra Żurowska, Head of the Department of Paediatrics, Nephrology and Hypertension of the MUG, funding in the amount of 11,960 mln PLN.

• RAFTING-2019 Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles [2019/ABM/01/00060]. Leader: Prof. Jan Maciej Zaucha, Head of the Department of Haematology & Transplantology of the MUG, funding in the amount of 19,859 mln PLN.

• MeDMD Evaluation of the effectiveness of the use of metoprolol in the prevention of cardiomyopathy and cardiac deaths in patients with Duchenne muscular dystrophy [2019/ABM/01/00026]. Leader: Dr. Habil. Joanna Kwiatkowska, Head of the Department of Paediatric Cardiology and Congenital Heart Defects of the MUG, funding in the amount of 17,904 mln PLN.

• STROACT Pharmacological reperfusion treatment of ischemic stroke in patients taking oral anticoagulants [2019/ABM/01/00084]. Leader: Prof. Bartosz Karaszewski, Head of the Department of Neurology of the MUG, funding in the amount of 20,795 mln PLN.

• COVID Phase III clinical research evaluating the efficacy and safety of Avigan (favipiravir) compared to standard care in accordance with the current AOTMiT recommendations in patients with SARS-CoV-2 infection [2020/ABM/COVID19/0060]. Leader: Dr. hab. Tomasz Smiatacz, Head of the Department of Infectious Diseases of the MUG, funding in the amount of 3,4 mln PLN

• CAREGIVER Cyclin-dependent kinase in triple-negative breast cancer – a „window of opportunity” study [2020/ABM/01/00008]. Leader: Dr. Habil. Elżbieta Senkus-Konefka from the Department of Oncology & Radiotherapy of the MUG. funding in the amount of 17,436 mln PLN.

• N-BURGUNG Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone-BGD with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line treatment [2020/ABM/01/00103]. Leader: Prof. Jan Maciej Zaucha, Head of the Department of Haematology & Transplantology of the MUG, funding in the amount of 17,117 mln PLN.

• WHARTON Assessment of the effect of Wharton’s jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases [2020/ABM/01/00110]. Leader: Beata Wajda, Ph.D. from the Division of Pulmonology of the MUG, funding in the amount of 12,514 mln PLN.

• MARFAN To evaluate the effectiveness of valsartan in treating aortic dilatation in children and young adults with genetically determined thoracic aortic disease, Marfan’s syndrome, a double-blind, placebo-controlled, multicentre study [2021/ABM/01/00011]. Leader: Lidia Woźniak-Mielczarek, Ph.D. from the Department of Paediatric Cardiology and Congenital Heart Defects of the MUG, funding in the amount of 9,682 mln PLN.

• POLPHITT Clinical trial in children and adolescents with primary malignant liver cancer – hepatoma (Hepatoblastoma) and hepatocellular carcinoma (Hepatocarcinoma) [2021/ABM/01/00009]. Leader: Prof. Piotr Czauderna, Head of the Department of Surgery and Urology for Children and Adolescents of the MUG, funding in the amount of 6,117 mln PLN.

• SERTRALINA The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved ejection fraction [2021/ABM/02/00024]. Leader: Prof. Paweł Zagożdżon, Head of the Division of Hygiene & Epidemiology of the MUG, funding in the amount of 9,944 mln PLN.

• WAKE-IN Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeting the criteria for CT eligibility (ASPECTS < 6) based on MRI criteria (DWI-FLAIR mismatch) [2021/ABM/02/00018]. Leader: Prof. Bartosz Karaszewski, Head of the Department of Neurology of the MUG, funding in the amount of 9,996 mln PLN.

• TRIMETAZYDYNA Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fraction [2021/ABM/03/00038]. Leader: Prof. Leszek Kalinowski, Head of Department of Clinical Analytics of the MUG. funding in the amount of 9,999 mln PLN.

• LEVOTAKO A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome [2022/ABM/01/00007]. Leader: prof. dr hab. Miłosz Jaguszewski (1st Department of Cardiology), funding in the amount of 11,273 mln PLN.